Evidence map›Paper›PMID 40016568›Full record

ArticleMolecular biotechnology2026

Cloning, Expression, Purification and Biological Activity Analysis of Recombinant Helicobacter pylori FabI as a Drug Target.

Tugba Gul Inci, Erennur Ugurel, Maria Orlenco, Selcan Akar, Recepcan Atlı, Ozkan Danis, Dilek Turgut-Balik

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tugba Gul InciDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, Davutpasa Campus, Esenler, 34220, Istanbul, Turkey.
Erennur UgurelDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, Davutpasa Campus, Esenler, 34220, Istanbul, Turkey.
Maria OrlencoDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, Davutpasa Campus, Esenler, 34220, Istanbul, Turkey.
Selcan AkarDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, Davutpasa Campus, Esenler, 34220, Istanbul, Turkey.
Recepcan AtlıDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, Davutpasa Campus, Esenler, 34220, Istanbul, Turkey.
Ozkan DanisDepartment of Chemistry, Faculty of Science, Marmara University, Istanbul, Turkey.
Dilek Turgut-BalikDepartment of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, Davutpasa Campus, Esenler, 34220, Istanbul, Turkey. dilekbalik@gmail.com.ORCID http://orcid.org/0000-0003-2417-4104

Funding

Yildiz Teknik Üniversitesi Yıldız Technical University Scientific Research Projects Coordination Department. Project Number: FBA-2021-4233
6 · The paper itself

Abstract

Helicobacter pylori (H. pylori) is an infectious agent colonized in gastric epithelium and leads to serious diseases such as ulcers and gastric carcinoma. H. pylori infection requires rapid and effective treatment options however existing therapies gradually diminish in efficacy due to the development of resistance. Type II fatty acid synthesis (FAS-II) pathway is a potent target for drug discovery studies because of its absence in humans and vital necessity for bacteria. In the last step of the synthesis, trans-2-enoyl-ACP is reduced to acyl-ACP with cofactor of NADH by enoyl-ACP reductase, FabI. In this study, recombinant HpFabI was successfully produced using an aLICator ligation-independent cloning and expression vector system for the first time. HpFabI gene was cloned, and then expressed, and the protein was purified in high yield. Recombinant HpFabI with a molecular mass of ~ 30 kDa was confirmed with Western Blot analysis and its concentration was determined in the range of 1.406-3.9495 mg/ml by Bradford Assay. The enzyme-specific activity of HpFabI was determined as 1.5871 nmol min

Indexed as

Bacterial ProteinsEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Helicobacter pyloriCloning, MolecularHumansRecombinant ProteinsBacterial ProteinsEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Recombinant ProteinsEnzymatic activityFabIFAS-IIHelicobacter pyloriProtein production

Identifiers

PMID40016568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.